FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125763124> ?p ?o ?g. }

• W2125763124 endingPage "2667" @default.
• W2125763124 startingPage "2658" @default.
• W2125763124 abstract "Abstract Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose–escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors. Patients and Methods: Patients aged 18 years or older with advanced solid tumors refractory to standard treatment were recruited. Regorafenib was administered orally for 21 days on/seven days off in repeating cycles, until discontinuation due to toxicity or tumor progression. Adverse events (AE) were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Pharmacokinetic profiles were measured after a single dose and on day 21. Pharmacodynamic and efficacy evaluations included tumor perfusion assessment using dynamic contrast-enhanced MRI, plasma cytokines, and tumor response using RECIST (v1.0). Results: Fifty-three patients were enrolled into eight cohorts at dose levels from 10 to 220 mg daily. The recommended dose for future studies was determined to be 160 mg daily, with a treatment schedule of 21 days on/seven days off in repeating 28-day cycles. The most common drug-related grade 3 or 4 AEs were dermatologic AEs (hand–foot skin reaction, rash), hypertension, and diarrhea. Pharmacokinetic analysis revealed a similar exposure at steady state for the parent compound and two pharmacologically active metabolites. Tumor perfusion and plasma cytokine analysis showed biologic activity of regorafenib. Three of 47 evaluable patients achieved a partial response (renal cell carcinoma, colorectal carcinoma, and osteosarcoma). Conclusion: Regorafenib showed an acceptable safety profile and preliminary evidence of antitumor activity in patients with solid tumors. Clin Cancer Res; 18(9); 2658–67. ©2012 AACR." @default.
• W2125763124 created "2016-06-24" @default.
• W2125763124 creator A5007018487 @default.
• W2125763124 creator A5021363817 @default.
• W2125763124 creator A5027572658 @default.
• W2125763124 creator A5039862784 @default.
• W2125763124 creator A5046175611 @default.
• W2125763124 creator A5048889187 @default.
• W2125763124 creator A5059144177 @default.
• W2125763124 creator A5059259953 @default.
• W2125763124 creator A5062364606 @default.
• W2125763124 creator A5064684263 @default.
• W2125763124 creator A5067135726 @default.
• W2125763124 date "2012-04-30" @default.
• W2125763124 modified "2023-09-27" @default.
• W2125763124 title "A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors" @default.
• W2125763124 cites W1968209756 @default.
• W2125763124 cites W1978139448 @default.
• W2125763124 cites W1983064145 @default.
• W2125763124 cites W2000076269 @default.
• W2125763124 cites W2011826559 @default.
• W2125763124 cites W2012708129 @default.
• W2125763124 cites W2015015957 @default.
• W2125763124 cites W2027335142 @default.
• W2125763124 cites W2029197596 @default.
• W2125763124 cites W2048983596 @default.
• W2125763124 cites W2055009621 @default.
• W2125763124 cites W2055437192 @default.
• W2125763124 cites W2061203237 @default.
• W2125763124 cites W2077178002 @default.
• W2125763124 cites W2083400761 @default.
• W2125763124 cites W2091872802 @default.
• W2125763124 cites W2108623236 @default.
• W2125763124 cites W2137758263 @default.
• W2125763124 cites W2139511378 @default.
• W2125763124 cites W2139819066 @default.
• W2125763124 cites W2140765540 @default.
• W2125763124 cites W2141639829 @default.
• W2125763124 cites W2158366593 @default.
• W2125763124 cites W4211075026 @default.
• W2125763124 doi "https://doi.org/10.1158/1078-0432.ccr-11-1900" @default.
• W2125763124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22421192" @default.
• W2125763124 hasPublicationYear "2012" @default.
• W2125763124 type Work @default.
• W2125763124 sameAs 2125763124 @default.
• W2125763124 citedByCount "284" @default.
• W2125763124 countsByYear W21257631242012 @default.
• W2125763124 countsByYear W21257631242013 @default.
• W2125763124 countsByYear W21257631242014 @default.
• W2125763124 countsByYear W21257631242015 @default.
• W2125763124 countsByYear W21257631242016 @default.
• W2125763124 countsByYear W21257631242017 @default.
• W2125763124 countsByYear W21257631242018 @default.
• W2125763124 countsByYear W21257631242019 @default.
• W2125763124 countsByYear W21257631242020 @default.
• W2125763124 countsByYear W21257631242021 @default.
• W2125763124 countsByYear W21257631242022 @default.
• W2125763124 countsByYear W21257631242023 @default.
• W2125763124 crossrefType "journal-article" @default.
• W2125763124 hasAuthorship W2125763124A5007018487 @default.
• W2125763124 hasAuthorship W2125763124A5021363817 @default.
• W2125763124 hasAuthorship W2125763124A5027572658 @default.
• W2125763124 hasAuthorship W2125763124A5039862784 @default.
• W2125763124 hasAuthorship W2125763124A5046175611 @default.
• W2125763124 hasAuthorship W2125763124A5048889187 @default.
• W2125763124 hasAuthorship W2125763124A5059144177 @default.
• W2125763124 hasAuthorship W2125763124A5059259953 @default.
• W2125763124 hasAuthorship W2125763124A5062364606 @default.
• W2125763124 hasAuthorship W2125763124A5064684263 @default.
• W2125763124 hasAuthorship W2125763124A5067135726 @default.
• W2125763124 hasBestOaLocation W21257631242 @default.
• W2125763124 hasConcept C111113717 @default.
• W2125763124 hasConcept C112705442 @default.
• W2125763124 hasConcept C121608353 @default.
• W2125763124 hasConcept C126322002 @default.
• W2125763124 hasConcept C143998085 @default.
• W2125763124 hasConcept C197934379 @default.
• W2125763124 hasConcept C2776248978 @default.
• W2125763124 hasConcept C2777793932 @default.
• W2125763124 hasConcept C2778570526 @default.
• W2125763124 hasConcept C2779984678 @default.
• W2125763124 hasConcept C29730261 @default.
• W2125763124 hasConcept C31760486 @default.
• W2125763124 hasConcept C526805850 @default.
• W2125763124 hasConcept C71924100 @default.
• W2125763124 hasConcept C90924648 @default.
• W2125763124 hasConcept C98274493 @default.
• W2125763124 hasConceptScore W2125763124C111113717 @default.
• W2125763124 hasConceptScore W2125763124C112705442 @default.
• W2125763124 hasConceptScore W2125763124C121608353 @default.
• W2125763124 hasConceptScore W2125763124C126322002 @default.
• W2125763124 hasConceptScore W2125763124C143998085 @default.
• W2125763124 hasConceptScore W2125763124C197934379 @default.
• W2125763124 hasConceptScore W2125763124C2776248978 @default.
• W2125763124 hasConceptScore W2125763124C2777793932 @default.
• W2125763124 hasConceptScore W2125763124C2778570526 @default.
• W2125763124 hasConceptScore W2125763124C2779984678 @default.
• W2125763124 hasConceptScore W2125763124C29730261 @default.

• next